MedTrace Logo

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

NCT03887520 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49001

Last updated 2022-01-28

No results posted yet for this study

Summary

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

Conditions

  • Cardiovascular Disease and Lipoprotein(a)

Interventions

DIAGNOSTIC_TEST

Blood draw for Lp(a)

Collect sample for Lipoprotein(a) testing

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-27
Primary Completion
2021-07-30
Completion
2021-07-30

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Czechia
  • Denmark
  • Egypt
  • France
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Israel
  • Italy
  • Japan
  • Lebanon
  • Malaysia
  • Mexico
  • Netherlands
  • Norway
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Romania
  • Russia
  • Slovakia
  • Slovenia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03887520 on ClinicalTrials.gov